Business
UCB extends its BIMZELX® "Get Yourself Back" direct-to-consumer campaign for the hidradenitis suppurativa community
UCB, a global biopharmaceutical company, today announced the expansion of its "Get Yourself Back" direct-to-consumer (DTC) advertising campaign for BIMZELX® (bimekizumab-bkzx). This campaign aims to raise awareness of BIMZELX and offers educational resources about both BIMZELX and hidradenitis suppurativa (HS), encouraging people living with the disease to talk with their healthcare provider about whether BIMZELX is right for them. BIMZELX is the first and only approved treatment for adults with
About this update from Ucb S.a.
[{"type":"list","items":[{"val":[{"type":"text","content":"Inspired by feedback from the hidradenitis suppurativa (HS) community, the campaign aims to raise awareness of BIMZELX and features a broad range of educational materials encouraging patients to discuss treatment options with their healthcare providers","length":267,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":267,"olType":false},{"type":"text","content":"ATLANTA, July 8, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the expansion of its "Get Yourself Back" direct-to-consumer (DTC) advertising campaign for BIMZELX® (bimekizumab-bkzx). This campaign aims to raise awareness of BIMZELX and offers educational resources about both BIMZELX and hidradenitis suppurativa (HS), encouraging people living with the disease to talk with their healthcare provider about whether BIMZELX is right for them. BIMZELX is the first and only approved treatment for adults with moderate-to-severe HS specifically designed to target interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines that drive the inflammatory process.1-2 "Get Yourself Back" aims to raise awareness of the challenges faced by those living with HS, featuring the stories of real people impacted by the condition.","length":907,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/UCB, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/UCB, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":95,"url":"https://media.zenfs.com/en/prnewswire.com/b8934a241b3f4be76014bb4ac3438a0c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xSTzopCi9exEzsCW8PHvIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE2NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b8934a241b3f4be76014bb4ac3438a0c","width":400,"height":95}},"href":"https://mma.prnewswire.com/media/677397/With_Tag_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"HS is a chronic, painful, and potentially debilitating inflammatory skin disease that is associated with systemic manifestations.3-4 Common symptoms include inflamed nodules that look like boils and abscesses.5 These can occur anywhere hair follicles are found, but usually develop in areas where skin rubs together, like armpits, the groin area, and the inner...